Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BPX-603
i
Other names:
BPX-603, BPX-603 GoCAR-T, HER2 GoCAR-T
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Bellicum
Drug class:
HER2-targeted CAR-T immunotherapy
Related drugs:
‹
AU-101 (0)
AU-105 (0)
CART-HER-2 (0)
CCT303-406 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HER2-Specific CAR T (0)
HypoSti.CAR-HER2 T (0)
MB-103 (0)
RB-312 (0)
RB-340 (0)
SC-CAR4BRAIN (0)
s (0)
SCRI-huCAR19v1 (0)
SCRI-huCAR19v2 (0)
SNC109 (0)
TGFBeta resistant HER2/EBV-CTLs (0)
TT16 (0)
AU-101 (0)
AU-105 (0)
CART-HER-2 (0)
CCT303-406 (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
HER2-Specific CAR T (0)
HypoSti.CAR-HER2 T (0)
MB-103 (0)
RB-312 (0)
RB-340 (0)
SC-CAR4BRAIN (0)
s (0)
SCRI-huCAR19v1 (0)
SCRI-huCAR19v2 (0)
SNC109 (0)
TGFBeta resistant HER2/EBV-CTLs (0)
TT16 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=220, Suspended, Bellicum Pharmaceuticals | Recruiting --> Suspended
over 1 year ago
Trial suspension • CAR T-Cell Therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
Torisel (temsirolimus) • BPX-603
over2years
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=220, Recruiting, Bellicum Pharmaceuticals | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
over 2 years ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
Torisel (temsirolimus) • BPX-603
almost4years
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
P1/2, N=220, Recruiting, Bellicum Pharmaceuticals
almost 4 years ago
Clinical • New P1/2 trial • CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
Torisel (temsirolimus) • BPX-603
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login